MedPage Today on MSN
Long-Term Givinostat Data Reinforce Safety Profile in Duchenne Muscular Dystrophy
Givinostat is an oral histone deacetylase (HDAC) inhibitor approved by the FDA in 2024 to treat Duchenne patients ages 6 years and older. Pathologic upregulation of HDAC occurs in DMD, leading to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback